Clinical trial

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

NCT06549465

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-08-06

PhasePHASE2

Study timeline

Study start (actual)2024-08-06Date precision: day

Registry last updated2026-10-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

PSMA PET-Positive Castration-Resistant Prostate Cancerunresolved

Interventions

In-111 rosopatamab tetraxetanBIOLOGICAL

45 kBq/kg Ac-225 rosopatamab tetraxetanBIOLOGICAL

45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetanBIOLOGICAL

60 kBq/kg Ac-225 rosopatamab tetraxetanBIOLOGICAL

Single dose 22 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetanBIOLOGICAL

Single dose 34 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetanBIOLOGICAL

Single dose 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetanBIOLOGICAL

55 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetanBIOLOGICAL

60 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetanBIOLOGICAL

Sponsors & collaborators

Convergent Therapeuticslead sponsor

Mapped research locations

New YorkNew York, United States3 BostonMassachusetts, United States1 St LouisMissouri, United States1 ClevelandOhio, United States1 San DiegoCalifornia, United States1 DurhamNorth Carolina, United States1 OmahaNebraska, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06549465 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.